Fulcrum Therapeutics, Inc. (FULC:NASDAQ) closed at $3.68 on October 23, 2026, unchanged on the day. The stock trades 76.6% below its 52-week high of $15.74 and 30.0% above its 52-week low of $2.83. Over the past year, it lost 60.1%. Fulcrum Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, FULC closed higher on 112 days (44%). Its best day was December 8, 2025 (+45.96%) and its worst was June 2, 2026 (-51.09%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 2 times.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. It has developed a proprietary product engine which employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle wasting disorder that leads to physical impairments and disability.
Find more stocks like FULC with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.